ImmuneWalk Therapeutics Announces Positive Results from Phase 1 SAD/MAD Study of IW-601, a First-In-Class Therapeutic with Broad Potential in Inflammatory and Aut…

Phase 1 Clinical Trial Met All Primary and Secondary Endpoints and Demonstrated Positive Safety, Pharmacokinetics, and ...